Interleukin 6 exacerbates the progression of warm autoimmune hemolytic anemia by influencing the activity and function of B cells.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 08 2023
14 08 2023
Historique:
received:
03
10
2022
accepted:
07
08
2023
medline:
16
8
2023
pubmed:
15
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
To explore the effect of IL-6 on the activity and secretory function of B cells and analyze its effect on clinical indicators and efficacy in wAIHA patients. This study included 25 hemolytic wAIHA patients, 13 remission patients, and 10 HCs. Plasma levels of various cytokines were detected using CBA. PBMCs were extracted from 12 hemolytic wAIHA patients and divided into three wells, stimulation with IL-6 and IL-6 + tocilizumab, the blank control wells were also set. After 48 h of in vitro cell culture, percentage of CD5
Identifiants
pubmed: 37580421
doi: 10.1038/s41598-023-40239-w
pii: 10.1038/s41598-023-40239-w
pmc: PMC10425344
doi:
Substances chimiques
Antigens, CD19
0
B7-1 Antigen
0
Interleukin-10
130068-27-8
Interleukin-6
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13231Informations de copyright
© 2023. Springer Nature Limited.
Références
Bass, G. F., Tuscano, E. T. & Tuscano, J. M. Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun. Rev. 13(4–5), 560–564 (2014).
doi: 10.1016/j.autrev.2013.11.010
pubmed: 24418298
Jäger, U. et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 41, 100648 (2020).
doi: 10.1016/j.blre.2019.100648
pubmed: 31839434
Barcellini, W., Zaninoni, A., Giannotta, J. A. & Fattizzo, B. New insights in autoimmune hemolytic anemia: From pathogenesis to therapy. J. Clin. Med. 9, 3859 (2020).
doi: 10.3390/jcm9123859
pubmed: 33261023
pmcid: 7759854
Tanaka, T. et al. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin. Immunol. 26(1), 88–96 (2014).
doi: 10.1016/j.smim.2014.01.009
pubmed: 24594001
Dienz, O. et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4
doi: 10.1084/jem.20081571
pubmed: 19139170
pmcid: 2626667
Hanlon, M. M. et al. STAT3 mediates the differential effects of oncostatin M and TNFα on RA synovial fibroblast and endothelial cell function. Front. Immunol. 10, 2056 (2019).
doi: 10.3389/fimmu.2019.02056
pubmed: 31555281
pmcid: 6724663
Zhu, H. et al. Expression of activated molecules on CD5
doi: 10.1007/s12185-016-1964-8
pubmed: 26968550
Zhao, M. et al. CD5+B lymphocytes secrete IL-10 rather than TGF-β1 which control the immune response in autoimmune haemolytic anaemia/ Evans syndrome. Autoimmunity 52(1), 12–20 (2019).
doi: 10.1080/08916934.2019.1576644
pubmed: 30784322
Group Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of autoimmune hemolytic anemia (2017) Red Blood Cell Disease (Anemia). Zhonghua Xue Ye Xue Za Zhi 38(4), 265–267 (2017).
Iuchi, Y. et al. Implication of oxidative stress as a cause of autoimmune hemolytic anemia in NZB mice. Free Radic. Biol. Med. 48(7), 935–944 (2010).
doi: 10.1016/j.freeradbiomed.2010.01.012
pubmed: 20079426
Muhammad Yusoff, F., Wong, K. K. & Mohd, R. N. Th1, Th2, and Th17 cytokines in systemic lupus erythematosus. Autoimmunity 53(1), 8–20 (2020).
doi: 10.1080/08916934.2019.1693545
pubmed: 31771364
Jiang, Q. et al. Role of Th22 cells in the pathogenesis of autoimmune diseases. Front. Immunol. 12, 688066 (2021).
doi: 10.3389/fimmu.2021.688066
pubmed: 34295334
pmcid: 8290841
Wang, Y. et al. B cell development and maturation. Adv. Exp. Med. Biol. 1254, 1–22 (2020).
doi: 10.1007/978-981-15-3532-1_1
pubmed: 32323265
Rosser, E. C. & Mauri, C. Regulatory B cells: Origin, phenotype, and function. Immunity 42(4), 607–612 (2015).
doi: 10.1016/j.immuni.2015.04.005
pubmed: 25902480
Stewart, A. et al. Single-cell transcriptomic analyses define distinct peripheral B cell subsets and discrete development pathways. Front. Immunol. 12, 602539 (2021).
doi: 10.3389/fimmu.2021.602539
pubmed: 33815362
pmcid: 8012727
Garaud, S. et al. CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J. Immunol. 186(8), 4835–4844 (2011).
doi: 10.4049/jimmunol.1003050
pubmed: 21398617
Renaudineau, Y. et al. An alternative exon 1 of the CD5 gene regulates CD5 expression in human B lymphocytes. Blood 106(8), 2781–2789 (2005).
doi: 10.1182/blood-2005-02-0597
pubmed: 15998834
Rose-John, S. Interleukin-6 family cytokines. Cold Spring Harb. Perspect. Biol. 10(2), a028415 (2018).
doi: 10.1101/cshperspect.a028415
pubmed: 28620096
pmcid: 5793756
Hirano, T. IL-6 in inflammation, autoimmunity and cancer. Int. Immunol. 33(3), 127–148 (2021).
doi: 10.1093/intimm/dxaa078
pubmed: 33337480
Lin, X. et al. Critical role of Th17 cells in development of autoimmune hemolytic anemia. Exp. Hematol. 40(12), 994-1004.e4 (2012).
doi: 10.1016/j.exphem.2012.08.008
Sebba, A. Tocilizumab: The first interleukin-6-receptor inhibitor. Am. J. Health Syst. Pharm. 65(15), 1413–1418 (2008).
doi: 10.2146/ajhp070449
pubmed: 18653811
Tanaka, T. & Kishimoto, T. Targeting interleukin-6: All the way to treat autoimmune and inflammatory diseases. Int. J. Biol. Sci. 8(9), 1227–1236 (2012).
doi: 10.7150/ijbs.4666
pubmed: 23136551
pmcid: 3491446
Dhillon, S. Intravenous tocilizumab: A review of its use in adults with rheumatoid arthritis. BioDrugs 28(1), 75–106 (2014).
doi: 10.1007/s40259-013-0076-8
pubmed: 24255004
De Matteis, A. et al. Tocilizumab for massive refractory pleural effusion in an adolescent with systemic lupus erythematosus. Pediatr. Rheumatol. Online J. 19(1), 144 (2021).
doi: 10.1186/s12969-021-00635-w
pubmed: 34530845
pmcid: 8444491
Yuzuriha, A. et al. Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy. Acta Haematol. 126(3), 147–150 (2011).
doi: 10.1159/000328426
pubmed: 21757886
García-Hernández, F. J. et al. Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus. Rheumatology (Oxford) 51(10), 1918–1919 (2012).
doi: 10.1093/rheumatology/kes072
pubmed: 22513150